NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary Hypercholesterolemia | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung Carcinoma | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple Sclerosis | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary HypercholesterolemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung CarcinomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimateNo phase registeredNCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in...Novartis Pharmaceuticals · Chronic Myeloid LeukemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimateNo phase registeredNCT05776888Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 YearsNovartis Pharmaceuticals · Relapsing Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimateNo phase registeredNCT05274425A 24-week rPMS Study in Real-world Setting for EnerzairNovartis Pharmaceuticals · AsthmaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT05849298A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNovartis Pharmaceuticals · Prostatic NeoplasmActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2026Sponsor estimateNo phase registeredNCT05217810A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®Novartis Pharmaceuticals · AsthmaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT05870579[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNovartis Pharmaceuticals · Breast CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 4NCT06372925Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial InfarctionNovartis Pharmaceuticals · Plaque, AtheroscleroticActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06388941Iptacopan in Patients With ANCA Associated VasculitisNovartis Pharmaceuticals · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06517732Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe...Novartis Pharmaceuticals · Hidradenitis SuppurativaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT04857372A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsNovartis Pharmaceuticals · MesotheliomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2027Sponsor estimatePhase 3NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesNovartis Pharmaceuticals · Acute Coronary SyndromeActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2027Sponsor estimatePhase 1/Phase 2NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid TumorsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2027Sponsor estimatePhase 3NCT05038735Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced...Novartis Pharmaceuticals · Breast CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 2NCT04544189Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and...Novartis Pharmaceuticals · Breast NeoplasmsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 1NCT07174063A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate CancerNovartis Pharmaceuticals · Metastatic Prostate Cancer (mCRPC)Active, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT02934568Ribociclib (LEE011) Rollover Study for Continued AccessNovartis Pharmaceuticals · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 1, 2027Sponsor estimate | NCT05552469Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNovartis Pharmaceuticals · Myeloid Diseases | NVSLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Feb 2, 2027Sponsor estimate | NCT04417621Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNovartis Pharmaceuticals · Melanoma | NVSLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT02934568Ribociclib (LEE011) Rollover Study for Continued AccessNovartis Pharmaceuticals · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid MalignanciesActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2027Sponsor estimatePhase 1NCT05552469Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNovartis Pharmaceuticals · Myeloid DiseasesActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2027Sponsor estimatePhase 2NCT04417621Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNovartis Pharmaceuticals · MelanomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 22 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.